P
Paulo Limjenco
Vice President of Business Operations at YPrime and ESG Strategy Lead focused on sustainability in clinical trials.
1
APPEARANCES
1
PODCASTS
012
DEC 30
JAN 6
JAN 13
JAN 20
JAN 27
FEB 3
FEB 10
FEB 17
FEB 24
MAR 3
MAR 10
MAR 17
MAR 24
MAR 31
APR 7
APR 14
APR 21
APR 28
MAY 5
MAY 12
MAY 19
MAY 26
JUN 2
JUN 9
JUN 16
JUN 23
JUN 30
JUL 7
JUL 14
JUL 21
JUL 28
AUG 4
AUG 11
AUG 18
AUG 25
SEP 1
SEP 8
SEP 15
SEP 22
SEP 29
OCT 6
OCT 13
OCT 20
OCT 27
NOV 3
NOV 10
NOV 17
NOV 24
DEC 1
DEC 8
DEC 15
DEC 22
DEC 29
JAN 5
JAN 12
JAN 19
JAN 26
FEB 2
FEB 9
FEB 16
FEB 23
MAR 2
MAR 9
MAR 16
MAR 23
MAR 30
APR 6
APR 13
APR 20
APR 27
MAY 4
MAY 11
MAY 18
MAY 25
JUN 1
JUN 8
JUN 15
JUN 22
JUN 29
JUL 6
JUL 13
JUL 20
JUL 27
AUG 3
AUG 10
AUG 17
AUG 24
AUG 31
SEP 7
SEP 14
SEP 21
SEP 28
OCT 5
Jun 15, 2026
S4: E7 Advancing Sustainability Through Smarter Clinical Trial Design
7:43

Sophia McLeodHOST
How do you think about this, Paulo, when we're thinking about those bigger impacts?
P
7:48Paulo LimgencoGUEST
I think with the industry a- as a whole, there is a common theme of efficiency.
P
7:53Paulo LimgencoGUEST
And then I guess a, a common example from our organization at Y Prime is the introduction of, um, an AI-backed and powered migration process.
P
8:03Paulo LimgencoGUEST
From, from our perspective, the ability to introduce efficiency through faster approvals, through cleaner data, more inclusive, the conducting of trials in general, is part of how we define that concept.
P
8:16Paulo LimgencoGUEST
So having the ability in, in our case, to reduce the number of, um, screen reports, um, containing errors, just a better quality screen reports, uh, or reduction in human-led migration errors for the localization process, it really had the ability to shorten our entire review process by over 60%.
P
8:37Paulo LimgencoGUEST
So there were actually, in addition to that, no additional error types introduced as part of that review.
23 MINS LATER
